Jeff Marc Goldberg - 29 Nov 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
President and CEO, Director
Signature
/s/ James Kastenmayer, by power of attorney
Issuer symbol
SYRE
Transactions as of
29 Nov 2022
Net transactions value
$0
Form type
4
Filing time
01 Dec 2022, 19:47:37 UTC
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGLE Employee Stock Option (right to buy) Award $0 +1,884,838 $0.000000 1,884,838 29 Nov 2022 Common Stock 1,884,838 $1.22 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 1/4 of the total award on November 29, 2023, and an additional 1/48 of the award will vest monthly thereafter until the option is 100% vested on November 29, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.